Active Trials

This study is for people who are hospitalized with COVID-19 who are at high risk for complications. Study participants will receive either (1) LAU-7b with standard of care, or (2) placebo with standard of care. The study is to see if LAU-7b prevents severe COVID-19 symptoms and death.

This study is for adults who are hospitalized with COVID-19. The study participants will receive NP-120 (Ifenprodil) with standard of care, or standard of care only, to see if NP-120 (Ifenprodil) improves clinical symptoms.

To determine the effectiveness of ozanimod as a treatment for COVID-19 patients.

This study is for front-line employees of provincial or municipal police force who do not have COVID-19. Study participants will receive VPM1002 (BCG vaccine) or placebo to see if the vaccine prevents COVID-19 infection or reduces its severity.

To determine whether EB05 can treat COVID-related Acute Respiratory Distress Syndrome (ARDS) and reduce ventilation rates and mortality.

This study is for people who are hospitalized for COVID-19 with severe symptoms. Study participants will receive either (1) otilimab with standard of care, or (2) placebo with standard of care. The study is to see if otilimab will prevent worsening of breathing and death.

This study is for healthy adults who do not have COVID-19. The study participants will receive Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5) (Ad5-nCoV). The study has two phases, Phase 1 is to see if the vaccine is safe to use in humans, and Phase 2 is to find an effective dose and timing for the vaccine.

This study is for people who are hospitalized for COVID-19. All study participants will get convalescent plasma (a part of blood) to see if it prevents death and reduces intubation, and to see whether people are able to leave the intensive care unit and the hospital faster.

This study is for people with COVID-19 who need supplemental oxygen because of COVID-19. All study participants will get ruxolitinib to see if it prevents them from needing machines to help with breathing or needing more supplemental oxygen.

This study compares tocilizumab with placebo in people who are hospitalized with severe COVID-19 to see if tocilizumab improves clinical symptoms.

This study is for people with COVID-19 who are not hospitalized. The study compares hydroxychloroquine and placebo to see if people who take hydroxychloroquine are less likely to be hospitalized or die.

This study is for people who are hospitalized with severe or critical COVID-19 infection. The study compares sarilumab and placebo to see if sarilumab prevents death and impoves clinical symptoms of COVID-19.

To see if dapagliflozan will prevent serious complications and death in people who are hospitalized with COVID-19. Study participants will receive dapagliflozan or placebo.

This study is for people with COVID-19 who are not hospitalized. Study participants will either (1) take icosapent ethyl, or (2) receive usual care. The study is to see if icosapent ethyl improves the results of blood tests related to COVID-19.

This is a study for adults hospitalized with COVID-19. Study participants will take ribavirin (Virazole) to see if it improves the clinical symptoms of COVID-19.

This is two studies for people with COVID-19, one for people who are not hospitalized, and one for people who are hospitalized. The study is to compare combinations of azithromycin, hydroxychloroquine or chloroquine, and interferon-beta to usual care. For people who are not hospitalized, the study is to see if the study drugs prevent hospitalization. For people who are hospitalized, the study is to see the study drugs prevent severe symptoms of COVID-19 or death.

This study is for people who are hospitalized with COVID-19. Study participants will receive either (1) tocilizumab with standard of care, or (2) standard of care, to see if tocilizumab prevents death and improves clinical symptoms.

This is a study for adults hospitalized with COVID-19 who need a machine to help them breathe. Study participants will receive mesenchymal stroma cells to see if the treatment is safe to use in humans, and to determine the maximum dose that can be safely used.

This study is for people who are hospitalized for COVID-19. The study compares therapeutic anticoagulation (low molecular weight heparin or unfractionated heparin) with standard care to see if therapeutic anticoagulation reduces intensive care unit admissions, reduces the need for machines to help with breathing, and/or prevents death.

This study is for people who have COVID-19, who are not admitted in the hospital, and who meet study-related high-risk criteria. The study compares colchicine to placebo to see if colchicine prevents hospitalization or death.

This study is for children hospitalized with COVID-19. Study participants will know which therapy they receive, and it will be either (1) standard of care, or (2) convalescent plasma and standard of care. The study is to see if convalescent plasma improves clinical symptoms of COVID-19 and to see if it prevents death.

This study is for adults living in long term care homes. Study participants receive favipiravir or placebo to see if favipiravir prevents COVID-19 outbreaks.

This study is for people who have been in close contact with someone who has COVID-19. The study is to see if lopinavir/ritonavir can prevent COVID-19 from being transmitted.

To investigate the safety of rhDNase1 and its effect on neutrophil extracellular traps (NETs) in COVID-19 infected patients.

This study is for people who are hospitalized for COVID-19. The study compares sarilumab to placebo to see if sarilumab improves clinical symptoms faster than placebo.

This study is for people who are hospitalized with COVID-19 who need a machine to help with breathing. Study participants will receive either (1) Bovine Lipid Extract Surfactant (BLES), or (2) standard treatment. The study is to see if BLES is safe to use and to see if BLES prevents death.

This study is to provide expanded access to remdesivir for people who are hospitalized with COVID-19.

To find out if immunization with IMM-101 will reduce the incidence of severe respiratory and COVID-19 infections in cancer patients.

To determine the effectiveness of vitamin D as a treatment for COVID-19 patients.

This study is for people who are diagnosed with difficult bacterial and viral lung infections including COVID-19. In the case of COVID-19, the study participants will inhale nitric oxide gas to see if they have faster recovery from COVID-19, need less oxygen therapy, and need less mechanical assistance with breathing.

This study is for people who are hospitalized with COVID-19 who are having trouble breathing. Study participants will receive either (1) standard of care, or (2) standard of care with Nitric Oxide delivered via the LungFit™ system. The study is to find out if Nitric Oxide will prevent worsened breathing.

This study is for people who have COVID-19 and either hospitalized or not hospitalized. The study compares Peginterferon Lambda-1A (an injected drug) and placebo to see if people who get Peginterferon Lambda-1A recover from COVID-19, and to see if they will recover faster.

This study is for patients who are hospitalized in the intensive care unit for COVID-19. The study compares high-dose Vitamin C with placebo to see if Vitamin C prevents sepsis, and therefore prevents death or persistent organ dysfunction.

To determine whether intravenous vitamin C, compared to placebo, reduces morbidity and mortality in patients hospitalized with COVID-19.

To determine whether intravenous vitamin C, compared to placebo, reduces morbidity and mortality in patients hospitalized with COVID-19.

This study is for people who work or live with patients who have COVID-19, or who work in places that have high risk of contact with patients who have COVID-19. Study participants will either (1) take standard precautions, or (2) take standard precautions and Nitric Oxide Releasing Solution (NORS) to see if NORS prevents COVID-19 infection. Study participants who become COVID-19 positive will take NORS to see if it reduces hospitalization, oxygen therapy, or the need for machines to help with breathing.

This study is for people hospitalized with COVID-19. The study compares LSALT peptide with placebo to see if LSALT peptide prevents Acute Respiratory Distress Syndrome (ARDS) and worsening COVID-19 symptoms.

To determine whether NaNO2 can effectively treat COVID-19 patients with acute respiratory distress syndrome (ARDS).

To assess the effectiveness and safety of ruxolitinib in the treatment of adult patients with COVID-19 pneumonia.

This study tests whether hydroxychloroquine can (1) prevent COVID-19 after someone has been exposed to SARS-CoV-2 coronavirus, and (2) prevent hospitalizations and severe symptoms in people who have tested positive for COVID-19. People in the study with take hydroxychloroquine or a placebo.

To evaluate whether high doses of vitamin D can treat COVID-19 symptoms.

To evaluate whether the addition of propranolol to a standard sedation regimen reduces the dose of sedative needed in critically ill COVID-19 patients requiring mechanical ventilation.

This study is for health care workers in the emergency department who are exposed to patients with COVID-19. The study compares hydroxychloroquine with placebo to see whether it prevents COVID-19. 

This study is for people who are hospitalized in the intensive care unit for COVID-19. The study measures whether different treatments and combinations of treatments will prevent death.

This study is for people who are living in an institute (rehabilitation, long term care facility, mental health facility, or veteran's care) who are at high-risk of complications and have been exposed to someone with COVID-19. Study participants will take hydroxychloroquine or placebo. The study is to see if hydroxychloroquine prevents COVID-19.

To assess the safety and effectiveness of the Coronavirus-Like Particle (CoVLP) COVID-19 vaccine.

This study is for people who are hospitalized with COVID-19 and need a machine to help them breathe. Study participants will receive different types of sedation drugs (isoflurane, sevoflurane, or standard of care) to see if it helps them recover from COVID-19.

To determine if Povidone iodine (PVP-I) is an effective treatment for patients diagnosed with COVID-19.

To determine if Camostat Mesilate can be used to treat COVID-19 patients.

This study is for people who are hospitalized for COVID-19. Study participants will receive heparin or usual care, to see if heparin prevents the need for a machine to help with breathing or death.

This study is for people who are hospitalized for COVID-19. The study compares 4 different treatments to see if they will improve clinical symptoms, and to see if it will improve symptoms faster. The study participants will know which treatment they are getting, which will be one of: (1) Lopinavir/ritonavir, (2) Hydroxychloroquine sulfate, (3) Baricitinib, or (4) standard care.

This study is for people who are admitted in the hospital with COVID-19. The study compares 4 different treatments to prevent death and improve clinical symptoms. The study participants will know which treatment they are getting, which will be one of: (1) standard care, (2) lopinavir/ritonavir with standard care, (3) hydroxychloroquine with standard care, or (4) remdesivir with standard care.

To evaluate nitric oxide-releasing drug (NORS) as treatment for COVID-19 in individuals with suspected mild COVID-19 infection.

This study is for people with COVID-19 who are not hospitalized. The study participants will either (1) receive standard treatment, or (2) use a device called Vielight RX Plus with standard treatment, to see if people who use Vielight RX Plus recover faster from COVID-19.